Inhibition of B-16 melanoma growth in vitro by prostaglandin D2.
Prostaglandin D2 was found to be a potent inhibitor of B-16 melanoma cell replication in vitro. The inhibition was dose-dependent between 3x10(-9)M and 3x10(-6)M (IC50 approximately 0.3 microM after 6 days). On a molar basis, PGD2 was a better inhibitor than PGA2 or 16, 16-dimethyl-PGE2-methyl ester (di-M-PGE2) and in higher concentrations (10(-6)-10(-7)M), comparable to retinoic acid. In higher concentrations, PGD2 inhibited DNA, RNA and protein synthesis. The B-16 melanoma cell line which we used synthesized arachidonic acid metabolites which comigrated with PGA2, PGD2, PGE2, and PGF2 alpha on a thin layer chromatography system.
D000818:Animals; D000970:Antineoplastic Agents; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D006801:Humans; D008545:Melanoma / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009374:Neoplasms, Experimental / Q000378:metabolism; D019301:Oleic Acid; D009829:Oleic Acids / Q000378:metabolism; D015230:Prostaglandin D2; D011453:Prostaglandins / Q000494:pharmacology*; D011457:Prostaglandins D / Q000494:pharmacology*; D012334:RNA, Neoplasm / Q000096:biosynthesis; D013997:Time Factors
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D009829:Oleic Acids; D011453:Prostaglandins; D011457:Prostaglandins D; D012334:RNA, Neoplasm; D019301:Oleic Acid; D015230:Prostaglandin D2